pancreatobiliary disease
Conditions
Interventions
Peruflubutane has been approved for intravenous administration to the human body. The insurance indication is the enhancement of liver mass lesion in ultrasonography. However, in this study, perflubut
Sponsors
ueki toshiharu
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Admitted patients with suspected pancreatobiliary tumor at departoment of gastroenterology in Fukuoka University Chikushi Hospital
Exclusion criteria
Exclusion criteria: Patients who fall under one or more of the following exclusion criteria are not included. (1) Patients with a history of hypersensitivity to the ingredients of this drug (2) Patients with are allergic to eggs or egg products (3) Patients with an arteriovenous (right and left) shunt in the heart and lungs (4) Patients with severe heart disease (5) patients with severe lung disease (6) Patients with the doctor in charge deems inappropriate for this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Differential diagnosis of patients with suspected biliary and pancreatic tumors by contrasting pattern after administration of perflubutanein | — |
Secondary
| Measure | Time frame |
|---|---|
| Determine the therapeutic effect of biliary tract cancer/oancreatic cancer after chemotharapy by administration of perflubutanein | — |
Contacts
Public Contacttoshiharu ueki
Fukuoka University Chikushi Hospital
Outcome results
None listed